Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics. - Wikidata - awgldk - TriplyDB

Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.

Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.

http://www.wikidata.org/entity/Q37488687

about

Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation New real-time PCR assay using locked nucleic acid probes to assess prevalence of ParC mutations in fluoroquinolone-susceptible Streptococcus pneumoniae isolates from France.In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone Prevalence of first-step mutants among levofloxacin-susceptible isolates of Streptococcus pneumoniae in north Lebanon.

P2860

Q34188814-13189B67-BE2F-4A02-835B-3BD6CCAD782E Q34510372-5219DA13-7389-4A2D-98D9-5598FA4E5EEF Q36422607-2B6E70E3-D4FD-4E88-85E0-2750DDC4EBD2 Q44468880-3261C0A5-3C03-4844-BAE0-B605FBFE4B79

P2860

Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.

http://www.wikidata.org/entity/Q37488687

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2004

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Designing fluoroquinolone brea ...... macokinetics-pharmacodynamics.

@en

Designing fluoroquinolone brea ...... macokinetics-pharmacodynamics.

@nl

type

label

Designing fluoroquinolone brea ...... macokinetics-pharmacodynamics.

@en

Designing fluoroquinolone brea ...... macokinetics-pharmacodynamics.

@nl

prefLabel

Designing fluoroquinolone brea ...... macokinetics-pharmacodynamics.

@en

Designing fluoroquinolone brea ...... macokinetics-pharmacodynamics.

@nl

P1433

Q37488687-304F5B1F-2786-4008-A462-EE9A53306DE8

P1476

Q37488687-B7321B36-76A1-4D25-A35E-C937F2C40076

P2093

Q37488687-12F5AF04-F8C0-4835-90BE-591E6ED82B9A

Q37488687-4919134E-60BB-4084-A6A3-6C5455FD6B33

Q37488687-5E897F5C-AE54-43D4-8544-9083C52489A6

Q37488687-9EBF7FB6-5C83-4644-978F-88C7AD65B05D

Q37488687-A0B75671-923B-4CCC-B058-F39C9768BC07

Q37488687-A570BA47-FFFC-45F1-AEF3-51FF2003B3EC

Q37488687-BDB0CCA3-1636-41F1-97C3-4B3B397FD33F

Q37488687-FD2654AE-D9E9-46C6-B9F5-8412348520DF

P2860

Q37488687-057F021F-31FD-49AA-A251-1AA15CAE8E86

Q37488687-06A24599-BA25-4881-AA64-5B4FF971C343

Q37488687-149C0FAD-F4E4-4FA6-A024-1B74C3739F76

Q37488687-3CA08022-4CE3-480B-936E-06C53DDA0351

Q37488687-64BE1DFA-992B-4796-8472-4D377F6A285C

Q37488687-6E9AFF3C-C223-4332-8D08-5ACE3CF3DD35

Q37488687-7E959127-A2AF-4D6D-9CE3-817006CDFEE1

Q37488687-8494511A-4B46-46E8-A591-B94DC2E74820

Q37488687-86D4774B-3F05-40E3-BA4E-ACA2B6B6D339

Q37488687-8B82E34B-B2D9-41AC-8F4E-A49D8E7302F9

P304

Q37488687-9A974532-5784-43E6-ADD2-90D6012B9C8C

P31

Q37488687-7F801E71-D78F-4C4D-BECE-B8D468F604EA

P356

Q37488687-CE8E15FE-FBD3-4943-A3AD-6E180C1D5C66

P407

Q37488687-E4F25B42-7E8E-4E69-9BAC-7A1E82903483

P433

Q37488687-766EE243-8101-479C-835A-8E37FE27C1EC

P478

Q37488687-018B74D2-2FF8-4AF5-B6A8-85A67629DB3B

P577

Q37488687-AD3DFDE7-773B-49EF-8E19-D825E61B03D2

P5875

Q37488687-E31385EE-1E94-4781-A240-319AEEC72E47

P698

Q37488687-42B2FCEF-397F-4734-BBA2-2976B759C502

P932

Q37488687-53E0993D-42D5-4283-BF7B-FFCA046B5737

P356

AAC.48.9.3630-3635.2004

P1433

Antimicrobial Agents and Chemotherapy

P1476

Designing fluoroquinolone brea ...... macokinetics-pharmacodynamics.

@en

P2093

A M Noreddin

http://www.w3.org/2001/XMLSchema#string

C G Siemens

http://www.w3.org/2001/XMLSchema#string

C J Hoban

http://www.w3.org/2001/XMLSchema#string

D J Hoban

http://www.w3.org/2001/XMLSchema#string

G G Zhanel

http://www.w3.org/2001/XMLSchema#string

H J Smith

http://www.w3.org/2001/XMLSchema#string

J Greisman

http://www.w3.org/2001/XMLSchema#string

K N Schurek

http://www.w3.org/2001/XMLSchema#string

P2860

DNA gyrase, topoisomerase IV, and the 4-quinolones

A critical review of the fluoroquinolones: focus on respiratory infections

Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.

Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.

Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.

Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002

Impact of pharmacodynamics on breakpoint selection for susceptibility testing.

Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins

Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.

Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae

P304

3630-3635

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.48.9.3630-3635.2004

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8384308

http://www.w3.org/2001/XMLSchema#string

P698

15328145

http://www.w3.org/2001/XMLSchema#string

P932

514724

http://www.w3.org/2001/XMLSchema#string